Lupin launches generic antibiotic inhalation solution in US
New Delhi: Drug firm Lupin said it has launched its antibiotic Tobramycin inhalation solution in the US market.
The company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a filing to BSE.
The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.
The product is indicated for the management of cystic fibrosis patients with P. aeruginosa, Lupin said.
As per IQVIA MAT April 2018 data, Tobramycin inhalation solution USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd